Quarterly report pursuant to Section 13 or 15(d)

Note 2 - Selected Balance Sheet Data

v3.8.0.1
Note 2 - Selected Balance Sheet Data
9 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]
N
ote
2.
Selected Balance Sheet Data
:
 
Available-For-Sale Investments:
 
The fair value of the Company's available-for-sale investments at
March 31, 2018
and
June 30, 2017
were
$89.8
million and
$66.1
million, respectively. The
$23.7
million increase in the Company’s available-for-sale investments was driven by a
$27.0
million increase in the fair value of the Company’s investment in ChemoCentryx, Inc (CCXI) from
$59.6
million at
June 30, 2017
to
$86.6
million at
March 31, 2018.
This increase was partially offset by the maturity of
$2.1
million in corporate bond securities held by Advanced Cell Diagnostics (ACD) and
$1.4
million in certificate of deposits held in China. The cost basis of the Company's investment in CCXI at
March 31, 2018
and
June 30, 2017
was
$29.5
million.
 
Inventories:
 
Inventories consist of (in thousands): 
   
March 31,
   
June 30,
 
   
2018
   
2017
 
Raw materials
  $
29,414
    $
22,074
 
Finished goods
   
59,172
     
38,077
 
Inventories, net
  $
88,586
    $
60,151
 
 
Property and Equipment:
 
Property and equipment consist of (in thousands):
   
March 31,
   
June 30,
 
   
2018
   
2017
 
Land
  $
7,064
    $
6,270
 
Buildings and improvements
   
172,305
     
158,495
 
Machinery and equipment
   
106,058
     
98,596
 
Property and equipment, cost
   
285,427
     
263,361
 
Accumulated depreciation and amortization
   
(142,648
)
   
(128,237
)
Property and equipment, net
  $
142,779
    $
135,124
 
 
Intangible Assets:
 
Intangible assets consist of (in thousands):
   
March 31,
   
June 30,
 
   
2018
   
2017
 
Developed technology
  $
292,825
    $
276,959
 
Trade names
   
88,961
     
87,092
 
Customer relationships
   
214,107
     
204,243
 
Non-compete agreements
   
3,286
     
3,264
 
Patents
   
1,242
     
633
 
Intangible assets
   
600,421
     
572,191
 
Accumulated amortization
   
(156,627
)
   
(120,149
)
Intangible assets, net
  $
443,794
    $
452,042
 
 
Changes to the carrying amount of net intangible assets for the
nine
months ended
March 31, 2018
consist of (in thousands):
 
Beginning balance
  $
452,042
 
Acquisitions
   
23,292
 
Other additions
   
796
 
Amortization expense
   
(34,611
)
Currency translation
   
2,275
 
Ending balance
  $
443,794
 
 
The estimated future amortization expense for intangible assets as of
March 31, 2018
is as follows (in thousands):
 
2018
  $
11,953
 
2019
   
47,125
 
2020
   
46,422
 
2021
   
46,035
 
2022
   
44,213
 
Thereafter
   
248,046
 
Total
  $
443,794
 
 
Goodwill:
 
Changes to the carrying amount of goodwill for the
nine
months ended
March 31, 2018
consist of (in thousands):
 
   
Biotechnology
   
Protein Platforms
   
Diagnostics
   
Total
 
Beginning balance
  $
254,930
    $
220,826
    $
103,270
    $
579,026
 
Acquisitions (Note 3)
   
27,686
     
-
     
113
     
27,799
 
Currency translation
   
3,416
     
454
     
(28
)
   
3,842
 
Ending balance
  $
286,032
    $
221,280
    $
103,355
    $
610,667
 
 
We evaluate the carrying value of goodwill in the
fourth
quarter of each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a quantitative assessment for all
three
of its reporting units during the
fourth
quarter of fiscal year
2017.
The quantitative assessment indicated that all of the reporting units had substantial headroom as of
June 30, 2017.
 
No
triggering events were identified during the quarter ended
March 31, 2018.
There has been
no
impairment of goodwill since the adoption of Financial Accounting Standards Board (“FASB”) ASC
350
guidance for goodwill and other intangibles on
July 1, 2002.
 
Other Assets:
 
Other Assets consist of (in thousands):
   
March 31,
   
June 30,
 
   
2018
   
2017
 
Investments
  $
24,181
    $
40,385
 
Other
   
2,883
     
3,617
 
Other assets
  $
27,064
    $
44,002
 
 
As of
March 31, 2018,
the Company had
$27.1
million of other assets compared to
$44.0
million as of
June 30, 2017.
The Company holds a
16.4%
ownership interest in Astute Medical, Inc. (Astute) and accounts for this investment under the cost method. During the
third
quarter the Company learned that Asute intended to accept an offer to sell the company to a
third
party. As a result of this triggering event, the Company completed an impairment assessment and determined that a portion of its investment in Astute was other-than-temporarily impaired and adjusted the carrying value of this investment by
$16.2
million during the
third
quarter to other income (expense) in the accompanying condensed consolidated Statement of Earnings and Comprehensive Income. The Company’s net investment in Astute was
$23.8
million at
March 31, 2018.